E2511

Uses your system voice; voice and rate in settings.

Snapshot

≈ 2 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

E2511, or E-2511, is a selective biased tropomyosin receptor kinase A (TrkA) positive allosteric modulator which is under development for the treatment of Alzheimer's disease. It is taken orally. The drug has been found to increase cholinergic signaling in preclinical research. The elimination half-life of E2511 is 3.2 hours in humans. E2511 is under development by Eisai. As of September 2024, it is in phase 1 clinical trials for Alzheimer's disease. A phase 1 clinical trial has been completed. The chemical structure of E2511 does not yet appear to have been disclosed.

E2511, or E-2511, is a selective biased tropomyosin receptor kinase A (TrkA) positive allosteric modulator which is under development for the treatment of Alzheimer's disease. It is taken orally. The drug has been found to increase cholinergic signaling in preclinical research. The elimination half-life of E2511 is 3.2 hours in humans. E2511 is under development by Eisai. As of September 2024, it is in phase 1 clinical trials for Alzheimer's disease. A phase 1 clinical trial has been completed. The chemical structure of E2511 does not yet appear to have been disclosed.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1374092555 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

2 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.